Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Psycheceutical Bioscience Inc BWVI

Psycheceutical Bioscience, Inc. is a bioscience company. The Company is engaged in developing cutting-edge delivery technologies to support safe psychedelic pharmaceutical medicines. The Company's technology is intended to deliver compounds across the blood-brain barrier while bypassing the gastrointestinal (GI) tract and liver, eliminating hallucinogenic effects and vastly reducing exposure to... see more

Recent & Breaking News (GREY:BWVI)

Historical Regulatory Filing Deficiences Continue to Stifle Psycheceutical Biosciences

Accesswire May 16, 2024

Psycheceutical Bioscience Strategically Pivots Into the Brain-Computer Interface (BCI) Space

Accesswire January 17, 2024

Dr. Neilank Jha Appointed as Executive Chairman and Chief Executive Officer of Psycheceutical Bioscience Inc.

Accesswire December 12, 2023

Psycheceutical Bioscience Launches Wefunder Crowdfunding Campaign for Safer Psychedelic Dosing

Accesswire November 1, 2023

Psycheceutical Announces Successful First Cohort Dosing; Moves to Dose Escalation in Phase I Trial of NeuroDirect Ketamine for PTSD

Accesswire August 10, 2023

Psycheceutical Bioscience Announces Completion of PCAOB Audit and Future Corporation Action Strategy

Accesswire August 1, 2023

First Patient Dosed in Psycheceutical's Phase I Study Exploring Topical Administration of Ketamine to Treat PTSD

Accesswire July 13, 2023

The Next Generation Of Mental Health Treatment: Psycheceutical Bioscience Inc.'s (OTCPK:BWVI) Novel Topical Ketamine Delivery

Accesswire April 18, 2023

Psycheceutical Bioscience, Inc. Named a 2023 Top 10 Biotech Startup by Life Sciences Review

PR Newswire April 13, 2023

Psycheceutical Hosts MAPS Founder and Psychedelic Industry Leader Rick Doblin at Its Drug Development Lab

GlobeNewswire March 29, 2023

Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect(TM) Ketamine Topical Cream in Treating PTSD

GlobeNewswire March 21, 2023

Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD

GlobeNewswire February 15, 2023

Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD

GlobeNewswire February 2, 2023

Psycheceutical Bioscience Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSD

GlobeNewswire January 26, 2023

Psycheceutical Announces Julian Bailes, M.D. as Board Member and Chief Medical Officer

GlobeNewswire January 10, 2023

Dr. Aric Logsdon Joins Psycheceutical Bioscience, Inc. as Company's Scientific Director

GlobeNewswire November 29, 2022

Psycheceutical Bioscience, Inc. Announces Medical Advisory Board

GlobeNewswire October 18, 2022

Kevin Harrington, Original Shark from Shark Tank and Futurist Zappy Zapolin to Open Wonderland 2022

Newsfile October 5, 2022

Psycheceutical Bioscience, Inc.'s Zappy Zapolin Added to The Benzinga Psychedelics Advisory Council

GlobeNewswire October 4, 2022

Psycheceutical Bioscience, Inc.'s CEO to Present at the Life Sciences Investor Forum on September 15

GlobeNewswire September 13, 2022